The Future of Retatrutide: What's After FDA Approval

Retatrutide's Phase 2 results (Jastreboff et al., NEJM 2023) represent a milestone in obesity medicine, but they are just the beginning. The future of retatrutide extends far beyond its initial approval, with expanded indications, combination therapies, and an entirely new competitive landscape taking shape. Here is what patients, providers, and the obesity medicine field can expect in the coming years.

Expanded Indications

MASH (Fatty Liver Disease)

Retatrutide's glucagon receptor activation makes it uniquely suited for metabolic dysfunction-associated steatohepatitis. Glucagon directly promotes hepatic fat oxidation, potentially making retatrutide the most effective pharmacological treatment for liver fat accumulation. Dedicated MASH trials within the TRIUMPH program are expected to provide liver biopsy data showing fibrosis improvement, which would support an additional FDA indication.

Cardiovascular Outcomes

Following semaglutide's cardiovascular benefit demonstrated in SELECT, a cardiovascular outcomes trial (CVOT) for retatrutide is expected. Given the more profound weight loss and metabolic improvements, retatrutide may demonstrate even greater cardiovascular risk reduction. A positive CVOT would dramatically expand insurance coverage and prescribing.

Chronic Kidney Disease

GLP-1 medications have shown renal protective effects. Retatrutide's more comprehensive metabolic profile may provide enhanced kidney protection, leading to potential studies in diabetic kidney disease.

Sleep Apnea

Tirzepatide recently showed remarkable results for obstructive sleep apnea. Retatrutide's greater weight loss may produce even more dramatic improvements, potentially becoming a first-line treatment for obesity-related sleep apnea.

Formulation Advances

Oral Formulation

Eli Lilly is actively developing oral formulations for its GLP-1 portfolio. An oral retatrutide would eliminate the injection barrier and dramatically expand the patient population willing to start treatment. Technical challenges (peptide absorption in the GI tract) are significant but being addressed with permeation enhancers and novel delivery technologies.

Higher Doses

The Phase 2 trial tested up to 12mg, but weight loss curves had not plateaued, suggesting even higher doses might produce greater effects. Phase 3 or post-approval studies may explore 16mg or higher doses for patients who need maximum weight loss.

The Competitive Landscape

Retatrutide will not be alone in the next-generation obesity market:

• Amycretin (Novo Nordisk): An amylin/GLP-1 dual agonist showing promising early results. May offer a different mechanism profile.
• Orforglipron (Eli Lilly): An oral GLP-1 that could become Lilly's entry-level option, with retatrutide for patients needing maximum effect.
• CagriSema (Novo Nordisk): Combines cagrilintide (amylin analog) with semaglutide for enhanced weight loss.
• Survodutide (Boehringer Ingelheim): A glucagon/GLP-1 dual agonist for MASH.
• Pemvidutide (Altimmune): Another GLP-1/glucagon dual agonist in development.

Combination Approaches

The future may include combining retatrutide with other medications for enhanced effects: retatrutide plus exercise mimetics for muscle preservation, retatrutide plus GLP-1/amylin combinations for even greater appetite suppression, retatrutide plus myostatin inhibitors to prevent muscle loss during rapid weight loss, and retatrutide plus anti-inflammatory agents for comprehensive metabolic correction.

Personalized Medicine

Genetic and biomarker-based approaches may eventually predict which patients respond best to retatrutide versus other GLP-1 medications. Pharmacogenomic testing could identify optimal responders, ideal dosing ranges, and patients at higher risk for specific side effects. This would enable truly personalized obesity treatment selection.

The Bigger Picture: Obesity as a Chronic Disease

Retatrutide's arrival accelerates the transformation of obesity medicine from a stigmatized, underserved field to a legitimate medical specialty with effective, evidence-based treatments. The future includes broader insurance coverage for obesity medications, integration of obesity treatment into primary care, reduced stigma as treatment becomes normalized, prevention strategies informed by GLP-1 receptor biology, and a fundamental shift in how society views and treats obesity.

Start Your Journey Now

The future of obesity medicine is bright, but effective treatment is available today. Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with the same medical commitment that will guide our retatrutide offering when it becomes available. Learn how Trimi works.

Frequently Asked Questions

Will there be something better than retatrutide?

Likely, eventually. Drug development is iterative, and next-generation compounds targeting four or more pathways, or using entirely different mechanisms, are in early development. However, retatrutide will likely remain a leading treatment for years after approval.

Will retatrutide come in pill form?

An oral formulation is a likely development priority for Eli Lilly, but technical challenges remain. An oral version is probably 3-5+ years after the injectable is approved.

Will retatrutide cure obesity?

No single medication will cure obesity, which is a complex, chronic condition driven by genetics, environment, and biology. Retatrutide is a powerful treatment tool, but ongoing use and lifestyle integration are needed for sustained results.

Should I wait for future drugs or start treatment now?

Start now. Obesity worsens over time, and the health benefits of current GLP-1 medications are proven. You can always transition to newer treatments as they become available. The best time to treat obesity is today.